Cybin (NASDAQ:HELP) Insider Acquires $1,121,000.00 in Stock

Cybin Inc. (NASDAQ:HELP) insider Eric So purchased 95,000 shares of the business’s stock in a transaction on Tuesday, September 1st. The shares were acquired at an average price of $11.80 per share, for a total transaction of $1,121,000.00. Following the completion of the purchase, the insider directly owned 4,265,014 shares of the company’s stock, valued at approximately $50,327,165.20. This trade represents a 2.28% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Cybin Stock Performance

Shares of HELP opened at $12.97 on Friday. The company’s 50-day simple moving average is $9.97 and its 200-day simple moving average is $6.89. Cybin Inc. has a 1 year low of $3.76 and a 1 year high of $14.35. The stock has a market capitalization of $980.66 million, a PE ratio of -4.29 and a beta of 0.63.

Cybin (NASDAQ:HELP) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11). On average, sell-side analysts predict that Cybin Inc. will post -2.95 earnings per share for the current year.

Analyst Ratings Changes

HELP has been the topic of a number of recent research reports. TD Cowen upped their price objective on Cybin from $8.00 to $62.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. Wells Fargo & Company began coverage on Cybin in a report on Monday, July 27th. They issued an “overweight” rating and a $16.00 target price for the company. Finally, Wall Street Zen raised Cybin from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 29th. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Cybin currently has a consensus rating of “Buy” and a consensus target price of $48.60.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. AXQ Capital LP purchased a new position in Cybin in the second quarter worth approximately $75,000. Pale Fire Capital SE purchased a new stake in shares of Cybin in the 2nd quarter valued at approximately $1,015,000. Millennium Management LLC increased its position in shares of Cybin by 1,388.5% in the 4th quarter. Millennium Management LLC now owns 1,028,549 shares of the company’s stock valued at $8,414,000 after purchasing an additional 959,448 shares during the last quarter. Osaic Holdings Inc. raised its holdings in shares of Cybin by 46.7% in the 2nd quarter. Osaic Holdings Inc. now owns 7,543 shares of the company’s stock valued at $63,000 after purchasing an additional 2,400 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of Cybin by 66.8% in the 2nd quarter. Bank of America Corp DE now owns 29,443 shares of the company’s stock valued at $247,000 after purchasing an additional 11,790 shares in the last quarter. Hedge funds and other institutional investors own 17.94% of the company’s stock.

Key Headlines Impacting Cybin

Here are the key news stories impacting Cybin this week:

• Positive Sentiment: Insider Paul Glavine bought 100,000 shares for approximately $1.25 million on September 8, increasing his direct ownership by 2.40%. Insider Eric H. L. So also purchased 100,000 shares for about $1.24 million, lifting his stake by 2.29%. These transactions follow additional purchases by both insiders in late August and early September, representing a notable pattern of open-market buying and likely supporting investor confidence. Eric So SEC filing Paul Glavine SEC filing
• Positive Sentiment: Cybin’s commercial operations are scheduled to receive investor exposure at the Morgan Stanley 24th Annual Global Healthcare Conference on September 16. CEO Michael Halstead is expected to participate in a fireside chat, potentially providing updates on the company’s psychedelic-based mental-health drug pipeline. Morgan Stanley conference announcement
• Neutral Sentiment: Reported short interest was zero shares with a zero-day days-to-cover ratio. However, the filing also showed an invalid “NaN” percentage change, making the data unreliable as an indicator of short-selling pressure.
• Negative Sentiment: Cybin remains an unprofitable clinical-stage biotechnology company. Its latest quarterly loss of $0.91 per share was worse than the expected $0.80 loss, and analysts project a full-year loss of approximately $2.95 per share. With no new trial result or regulatory approval reported, valuation and future financing needs remain important risks after the stock’s sharp advance.

About Cybin

Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.